Triple-negative breast cancer responds to new dual-target therapy

New Pre-Med Protocol Improves Ocrelizumab Treatment for Multiple Sclerosis
January 14, 2019
No, it’s not contagious
January 15, 2019
Show all

Triple-negative breast cancer responds to new dual-target therapy

An experimental therapy that targets two growth pathways reduced cancer cell proliferation and spread in mice with triple-negative breast cancer.

An experimental therapy has shown promising results in fighting a particularly aggressive breast cancer with limited treatment options.

A recent study has revealed that the novel treatment decreased the growth and spread of triple-negative breast cancer in mice.

The approach uses a protein to block two growth mechanisms that help the breast cancer cells to multiply and migrate.

The protein, which has the name tubulointerstitial nephritis antigen-like 1 (TINAGL1), occurs naturally in the body.

The study suggests that a synthetic, or recombinant, version of TINAGL1 could reduce the growth and spread of triple-negative breast cancer.

A report on the findings now features in the journal Cancer Cell.

“People have tried,” says senior study author Yibin Kang, a professor of molecular biology at Princeton University in New Jersey, “to block the spread of this form of cancer, but attempts so far have failed because if you try one approach, the cancer cells compensate by finding a way to escape.”

“With this new approach, the treatment blocks both pathways at the same time,” he adds.

Read on: Triple-negative breast cancer responds to new dual-target therapy

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.